

ASX RELEASE

Volpara Quarterly Results and Investor Conference Call

Wellington, NZ, 12 October 2017: <u>Volpara Health Technologies</u> ("Volpara"; ASX: VHT), a digital health company focused on the early detection of breast cancer by improving quality of screening, is pleased to advise it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 30 September 2017 (Q2 FY18) on 17 October 2017.

Investors are invited to join a conference call with CEO, Dr Ralph Highnam and CFO Craig Hadfield at 9am AEDT (11am NZDT) Wednesday 18 October 2017.

To pre-register please follow this link:

https://services.choruscall.com.au/diamondpass/volparahealthtechnologies-440122-invite.html

You will receive a calendar notification with dial-in details and PIN for fast-track access to the call.

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 35 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO Volpara Health Technologies ralph.highnam@volparasolutions.com t: +64 21 149 0541 Kyahn Williamson WE Buchan kwilliamson@buchanwe.com.au t: +61 3 9866 4722